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Syncytial Virus Outbreak in a Stem Cell
Transplantation Unit: The Role of Palivizumab
Christelle Kassis,1 Richard E. Champlin,2 Ray Y. Hachem,1 Chitra Hosing,2 Jeffrey J. Tarrand,3
Cheryl A. Perego,1 Joyce L. Neumann,2 Issam I. Raad,1 Roy F. Chemaly1Respiratory syncytial virus (RSV) is a common community-acquired virus that causes upper and lower respi-
ratory tract infections in children, hematologic malignancy patients, and hematopoietic stem cell transplant
(HSCT) recipients. Nosocomial transmission of RSV in immunocompromised patients can significantly affect
morbidity, mortality, and duration of hospitalization. Stringent infection control measurements are needed to
control further hospital transmission. Prophylactic palivizumab was found to result in a significant reduction
in hospitalization rates in high-risk children. In this article, we report a nosocomial outbreak of RSV in an
adult HSCTunit (4 pods) from January 16 to February 4, 2004, including the infection control interventions
used and the prophylactic administration of palivizumab in high-risk patients. Active surveillance identified 5
cases, a substantial increase from previous seasons (2 or 3 cases per season). All infected patients were iso-
lated to 1 nursing pod and placed on contact isolation. All patients on the HSCTunit underwent rapid RSV
antigen screening using nasal washes; this was repeated 1 week later, and 1 additional RSV case was identified.
Patients identified to be at increased risk for RSV infection received prophylactic palivizumab. Routine
screenings of the staff and visitors were undertaken. All patient and visitor areas were thoroughly cleaned
with bleach. We educated health care workers about RSV transmission, highlighting proper hand hygiene
and contact precautions. Four of 6 patients with RSV infection developed RSV pneumonia, and 2 of these
patients died. Staff and visitors with upper respiratory symptoms were screened, and all were negative
for RSV. Prophylactic palivizumab was administered in 16 patients who tested negative for RSV, but were con-
sidered to be at increased risk for RSV infection. None of these patients developed RSV infections. An RSV
outbreak was controlled using prompt preventive measures, including cohorting patients, with a dedicated
health care staff; contact isolation of patients; strict adherence to hand hygiene; and screening of visitors, fam-
ily members, and health care staff for upper respiratory infection symptoms. Immunoprophylaxis with pal-
ivizumab, administered to high-risk patients, complemented strict infection control intervention. Thus,
the role of palivizumab in the control of RSV hospital outbreaks merits further investigation.
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Respiratory syncytial virus (RSV) is a well-known
cause of lower respiratory tract infections in young
children [1], and is now increasingly recognized as an
important cause of respiratory infections in adults,
especially in the elderly and immunocompromised
patients [2]. By the age of 2 years, almost all children
have been infected with RSV [3], but naturally acquired
immunity is incomplete, and reinfection is common [4].
The clinical features of reinfections are generally
mild in immunocompetent patients, and the duration
of viral shedding is relatively short. However, RSV
infections have been associated with high morbidity
and mortality rates (70%-100%) and prolonged viral
shedding in both autologous and allogeneic adult
stem cell transplant (HSCT) recipients [5,6]. The1265
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Figure 1. Incidence of nosocomial RSV in stem cell transplant unit
during the last 3 winter seasons
1266 Biol Blood Marrow Transplant 16:1265-1271, 2010C. Kassis et al.disease incidence varies seasonally, with a peak
from November to April in the northern hemisphere.
Outbreaks of RSV infections have been reported
among nursing home patients and institutionalized
young adults [7-9], but few reports have documented
nosocomial RSV outbreaks among HSCT patients
[10-12].
Active infection control surveillance strategies of
RSV and other community-acquired respiratory
viruses play crucial roles in identifying nosocomial
transmission and controlling outbreaks. Studies have
suggested that hand washing after patient contact,
the use of gowns and gloves, and cohorting of staff
and patients are effective preventive strategies [13,14].
Palivizumab (Synagis. MedImmune, Inc., Gaith-
ersburg, MD, USA) is a humanized monoclonal
antibody directed against the F glycoprotein of RSV;
it was approved for the prophylaxis of RSV disease in
high-risk infants [15-17]. However, its effectiveness
in high-risk adults has never been evaluated.
In this article, we describe an outbreak of nosoco-
mial RSV among HSCT unit patients at our institu-
tion, which was managed using strict infection
control interventions and palivizumab immunopro-
phylaxis in high-risk adult HSCT patients.METHODS
Epidemiologic Investigation
The HSCT unit at The University of Texas M.D.
Anderson Cancer Center (Houston, Texas) is a 52-bed
unit divided into 4 pods (NE, NW, SW, and SE).
From October through March each year, we monitor
community- or hospital-acquired respiratory viral in-
fections in hematologic malignancy patients. Patients
with symptoms of upper respiratory infection undergo
RSV and influenza screening, performed using rapid
antigen tests and cultures of nasal washes.
At our institution, the incidence of hospital-
acquired RSV infection peaks in January and February,
with a steady rate of 0.2 and 0.3/1000 patients’ days in
2002 and 2003, respectively (Figure 1). However, in
January and February 2004, active surveillance of
symptomatic patients identified 5 HSCT patients
with nosocomial RSV infections. This number
represented a substantial increase in incidence of
hospital-acquired RSV (0.74/1000 patients’ days)
when compared to that of previous seasons. We initi-
ated strict infection control measures and investigated
the outbreak on February 4th.Identification of Additional Cases
Nasal washes from all HSCT patients on all 4 pods
were collected and sent for rapid RSV antigen screen-
ing tests on February 4th; the same day strict infectioncontrol measures were implemented. All health care
workers who reported upper respiratory symptoms
were restricted from patient contact and underwent
rapid RSV antigen testing. A sign was placed at the
entrance of each pod that stated that all visitors and
familymembers were required to checkin at the nurses’
station prior to entering patient rooms.
A questionnaire, ‘‘Visitor Questionnaire for Upper
Respiratory Symptoms,’’ was distributed to all visitors
at the nurses’ station. The questionnaire included 2
questions: ‘‘Do you currently have symptoms of
a cold, that is, are you sneezing, coughing, have a runny
nose, sore throat or fever?’’ and ‘‘Have you had close
contact with someone that has a cold within the past
7 days?’’ All individuals who responded yes to either
question were not granted visitation. All visitors who
responded no were required to wear a sticker that
read, ‘‘I have been screened today (date) and I am
safe.’’ The nursing staff kept a record of all visitors
who had been screened for upper respiratory signs.
This system ensured that everyone entering patient
rooms had undergone screening.
One week later after the screening process had
been established, all patients underwent follow-up
rapid RSV antigen screening of nasal washes.
Definitions
Upper respiratory RSV infection was defined as
rhinorrhea, nasal or sinus congestion, otitis media,
pharyngitis, or cough with a clear chest radiograph,
with or without fever. RSV pneumonia was defined
as an acute respiratory illness in association with signs
or symptoms of lower respiratory tract disease and new
radiographic infiltrates. Infection was considered nos-
ocomial if respiratory symptoms developed .5 days
after hospital admission.
Laboratory Methods
Nasal washes were collected for rapid antigen de-
tection using the Light Diagnostics Simufluor RSV/
FluA immunofluorescence assay kit (Millipore Corpo-
ration, Bedford, MA,USA; catalog no. 3129). All spec-
imens were placed in a viral transport medium on ice or
refrigerated immediately and transported to the
Pod NE
Pod NW
Infection control team was notified. 
Outbreak investigation was launched. 
All patients on all 4 pods were 
screened with rapid RSV Antigen test 
on a nasal wash
Biol Blood Marrow Transplant 16:1265-1271, 2010 1267RSV Outbreak in a HSCT Unitlaboratory on ice. Specimens were treated and centri-
fuged into pellets; any specimens that did not contain
sufficient respiratory epithelial cells were recollected.
Upon treatment with the Simufluor RSV/Flu A re-
agent, the RSV antigen-antibody complex exhibits an
apple-green fluorescence, whereas uninfected cells
will stain a dull red [18]. Results were obtained within
2 hours and immediately reported to the clinician. The
sensitivity and specificity of this test is between 85%
and 100% [18].Patient 1 
Pod SW Patient 2
Patient 3
Patient 5
Pod SE Patient 4
Patient 6
2/4/20042/2/20041/28/20041/27/20041/22/20041/16/2004
Figure 2. Timeline of RSV infections among the 6 identified patientsRESULTS
Epidemiologic Investigations
On January 16, 22, and 27, 2004, 3 patients admit-
ted to the SW pod were diagnosed with nosocomial
RSV infections. Patients 1 and 3 had evidence of pneu-
monia, whereas patient 2 had an upper respiratory
infection with a negative chest X-ray. On January 28,
patient 4, admitted to the SE pod, was diagnosed
with pneumonia secondary to RSV. Five days later,
on February 2nd, patient 5, admitted to the SW pod
was diagnosed with RSV pneumonia (Figure 2). This
increase in incidence of nosocomial RSV infection
was higher than that in previous years, although not
statistically significant.We initiated an outbreak inves-
tigation as part of our infection control plan when 2 or
more nosocomial RSV or other respiratory virus infec-
tions are occurring in patients in the same vicinity and
around the same period of time (Figure 1). All HSCT
patients and health care workers on all 4 pods were
screened using a rapid RSV antigen test of nasal
washes. Six health care workers were found to have up-
per respiratory symptoms, but none were positive for
RSV antigen. On February 4th, a sixth patient was di-
agnosed with a RSV upper respiratory tract infection
(Figure 2). Table 1 shows the demographic and clinical
characteristics of all 6 patients. All patients were
treated with aerosolized ribavirin and palivizumab
for at least 7 days. Of the 4 patients with RSV pneumo-
nia, 2 died.Interventions
All RSV-infected patients, along with designated
nurses, a respiratory care therapist, and a phlebotomist
were moved to the RSV pod (SW). All patients on this
pod with or without RSV infection were placed on
contact isolation, with masks. No additional patients
were admitted to the pod.
All visitors with upper respiratory symptoms or
a fever or who had been exposed to individuals with
colds within the past 7 days were prohibited from
entering patient rooms. The infection control practi-
tioners conducted an intensive educational program
for employees on all 4 pods that emphasized properhand hygiene, and strict adherence to contact isolation
with mask. Housekeeping performed environmental
decontamination with bleach, and established more
frequent, rigorous cleaning schedules for patient
rooms, nursing areas, restrooms, break rooms, and
waiting areas.
We then identified HSCT patients who may be at
high risk for complications if RSV infection is acquired
using the following criteria: allogeneic transplantation,
preengraftment, graft-versus-host disease (GVHD),
high-dose steroids, or neutropenia with absolute neu-
trophil count \500 cells/mL. Sixteen patients met
these criteria. All 16 were negative for RSV antigen
and were given a single dose of 15 mg/kg of intrave-
nous palivizumab. One week later, we performed
follow-up screening of all HSCT patients; no new
cases of RSV infection were identified. None of the
16 high-risk HSCT patients who had received palivi-
zumab developed RSV infections (Tables 2 and 3 sum-
marize all published RSV outbreaks in the pediatric
and adult populations).
Twenty days later, control measures were dis-
cussed and reviewed. Contact isolation was discontin-
ued for all non-RSV-infected patients. Screening of
symptomatic health care staff and visitors was contin-
ued. The use of masks and gloves during patient con-
tact was reinforced.DISCUSSION
RSV is a frequent cause of both acute upper and
lower respiratory tract infections, and the severity of
clinical manifestation depends on patient age and
health status. In immunocompromised patients, such
as hematopoietic HSCT recipients, RSV upper respi-
ratory disease may progress to fatal viral pneumonia
[19]. In a previous study conducted at our institution,
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1268 Biol Blood Marrow Transplant 16:1265-1271, 2010C. Kassis et al.RSVwas isolated in 31% of 343 cases of respiratory ill-
ness from July 1, 2000, to July 30, 2002, in leukemia
and HSCT patients [20]. Pneumonia developed in
36% (39 of 107) of RSV cases, and 6 of 36 (17%) pa-
tients treated for RSV pneumonia died. These high
rates of pneumonia and death have been confirmed
at other centers [21].
Early treatment (before respiratory failure occurs)
with aerosolized ribavirin, alone or in combination
with immunotherapy, is key to reducingmortality inpa-
tients with established pneumonia [22,23]. Further-
more, the early use of aerosolized ribavirin-based
therapy in immunocompromised patients with isolated
upper respiratory symptoms can decrease the rate of
progression to pneumonia [20]. Thus, routine screen-
ing ofHSCTpatients with upper respiratory symptoms
is important, especially during high seasonal peaks.
In this article, we described an outbreak of nosoco-
mial RSV in which 6 HSCT patients developed RSV
infections. Two patients had isolated upper respiratory
involvement, and 4 developed pneumonia. All 6
patients were promptly started on aerosolized ribavirin
treatment, but 2 developed severe respiratory failure
and died.
Stringent infection control measures, including
cohorting RSV-infected patients and healthy staff
members to 1 pod, placing all patients on contact iso-
lation, and screening visitors and staff, were imple-
mented to control the outbreak. RSV is highly
contagious, and rapid spread among hospitalized pa-
tients has been documented. The virus survives up to
7 hours on countertops, gloves, paper tissues, and
clothes and 30 minutes on skin [24]. Transmission oc-
curs primarily through inoculation of nasopharyngeal
or ocular mucous membranes after contact with virus
containing secretions or fomites [25]. Furthermore,
transmission through large aerosol droplets has been
implicated [26]. Hence, vigorous handwashing and
strict application of contact isolation, including surgi-
cal masks and eye protection, may be the most impor-
tant measures of preventing nosocomial spread
[27,28]. Isolating patients and staff, in which patients
are placed in private rooms or with other RSV-
infected patients and health care workers are restricted
from caring for uninfected patients, is extremely effec-
tive at controlling further nosocomial transmission
[28,29]. Finally, restricting visitors with upper
respiratory symptoms from patient contact and
continuously educating all personnel and family
members should be implemented in every outbreak
setting [28].
However, in a recent neonatal intensive care unit
RSV outbreak [30], the above infection control mea-
sures were not effective at preventing further RSV
infections with significant morbidity. Palivizumab
therapy was initiated for all infants admitted to the
unit, and no further cases were noted. Palivizumab is
Table 2. Summary of RSVOutbreaks in the Pediatric Population
References (No.)
Unit Level
of Care
(No. of Beds)
Date of the
Outbreak
No. of Infants
on the Ward at
Time of Outbreak
No. of Infants
Infected
with RSV
No. of Deaths
Secondary to
RSV Infection
No. of Infants
Who Received
Prophylactic
Palivizumab
No. of RSV
Infections after
Administration
of Palivizumab
Salcedo et al. [45] NICU (17)/Intermediate
care (15)
Jan-00 56 4 0 All infants 0
Cox et al. [46] NICU (18) Nov/Dec 1999 17 7 1 8 (high risk) 0
Kilani [47] NICU (20) 2001 20 8 1 All infants 0
Heerens et al. [48] Neonatal critical
care center (NA)
Feb-98 NA 3 1 none N/A
Heerens et al. [48] Neonatal critical
care center (NA)
Apr-98 NA 6 1 none N/A
Abadesso et al. [30] NICU (26) Nov-98 NA 3 0 none N/A
Abadesso et al. [30] NICU (26) Apr-98 19 8 1 All infants 0
Halasa et al. [49] NICU (37)/Intermediate
care (19)
NA NA 9 0 All not infected
infants
0
Kurz et al. [50] NICU (12) Jan-07 11 1 0 All infants 0
NICU indicates neonatal intensive care unit; NA, not available; N/A, not applicable; RSV, respiratory syncytial virus.
Biol Blood Marrow Transplant 16:1265-1271, 2010 1269RSV Outbreak in a HSCT Unita humanized monoclonal antibody that specifically in-
hibits an epitope at the A antigenic site of the F protein
of RSV subtypes A and B. Antibody binding to the
F protein has 2 effects. First, it prevents cellular infec-
tion by preventing the viralmembrane from fusingwith
the respiratory epithelial cell membrane. Second, it
prevents cell-to-cell spread of the virus, which prevents
the formation of syncytia and the release of inflamma-
tory mediators in the lungs [31]. These properties pro-
vide the rationale for its clinical use. In the Impact-RSV
trial [32], a randomized, double-blinded, placebo-con-
trolled multicenter study, prophylactic palivizumab
resulted in a significant reduction in hospitalization
rates in high-risk children; this finding led to its U.S.
Food and Drug Administration approval of palivizu-
mab for RSV prophylaxis in high-risk children in
June 1998. Palivizumab was administered intramuscu-
larly eachmonth during the cold season, at 5 doses of 15
mg/kg, in 1502 high-risk children; it resulted in a 55%
reduction in the rate of RSV hospitalization (10.6% in
the placebo group versus 4.8% in the palivizumabTable 3. Summary of RSVOutbreaks in Adults
RSV Outbreaks in Immunoc
References
Unit Level of
Care (No. of Beds)
Date of the
Outbreak
No. of
Patients
on the Ward at
Time of Outbreak
Harrington et al. [11] BMTunit Jan/Apr 1990 NA
Jones et al. [51] Hematology/Oncology
ward (14)
Feb/Apr 1997 NA
Abdallah et al. [10] BMTunit May/Sep 2001 NA
Current study BMTunit Jan/Feb 2004 52
RSV Outbreaks in Immun
Sorvillo et al. [52] Nursing home Mar/May
Huang et al. [53] Psychiatry ward Aug 2005
Caram et al. [54] Long-term care facility Jan/Feb 2008
BMT indicates bone marrow transplant; NA, not available; N/A, not applicablegroup,P\.001). Premature childrenwith no broncho-
pulmonary dysplasia experienced a 78% reduction in
the RSV hospitalization rate (8.1% versus 1.8%,
P\ .001), and children with bronchopulmonary dys-
plasia experienced a 39% reduction (12.8% versus
7.9%, P 5 .038). Subsequent studies confirmed these
results [17,33-39]. The American Academy of
Pediatrics acknowledges that palivizumab may be
beneficial in children with severe immunodeficiencies
[40]. In a decision analysis model designed to deter-
mine the effect of prophylactic palivizumab onmortal-
ity in pediatric stem cell transplant recipients, the
absolute survival rate increased from 83% to 92%
with palivizumab [41].
Palivizumab is used, alone or in combination with
aerosolized ribavirin, in the treatment of, respectively,
upper and lower RSV respiratory tract infections
[20,23,42]. However, data on its use in adult HSCT
patients remains limited. Palivizumab has an
excellent safety profile, and may be beneficial at
preventing and treating RSV infections inompromised Adults
No. of Patients
Infected with RSV
No. of Deaths
Secondary to
RSV Infection
No. of Patients
Who Received
Prophylactic
Palivizumab
No. of RSV
Infections after
Administration
of Palivizumab
31 14 (all had
pneumonia)
None N/A
8 (including 5
posttransplantation)
0 None N/A
16 2 (Both had
pneumonia)
None N/A
6 2 16 (high-risk) 0
ocompetent Adults
NA 40 8 None N/A
25 8 patients and 4 HCW 0 None N/A
52 22 0 None N/A
; HCW, health care worker; RSV, respiratory syncytial virus.
1270 Biol Blood Marrow Transplant 16:1265-1271, 2010C. Kassis et al.immunocompromised adults but bearing in mind its
prohibitive cost [43]. In the outbreak described in
this article, palivizumab was prophylactically adminis-
tered to all HSCT patients at high risk for RSV infec-
tion, including all allogeneic and preengraftment
transplant recipients, GVHD patients on high-dose
steroids, and severely neutropenic patients (absolute
neutrophil count\500). No upper or lower RSV in-
fections occurred in these patients. The use of prophy-
lactic palivizumab may have contributed to preventing
the further nosocomial spread of RSV, but the direct
benefit from this intervention could not be assessed
in our study as other simultaneous infection control
measures were implemented as well.
In conclusion, active surveillance of all symptom-
atic patients and health care workers, especially dur-
ing RSV season, remains the cornerstone for
identifying RSV outbreaks. The prevention strategy
should include assiduous handwashing and strict con-
tact isolation and mask use. Patients shed RSV
asymptomatically for days before and after resolution
of the infection; thus, efforts should be made to iso-
late these patients and assign designated personnel
to care for them. Continuous screening of patients,
health care workers, and visitors, especially during
outbreaks, is extremely helpful in preventing further
nosocomial RSV spread. Furthermore, intensive edu-
cational programs help increase awareness of RSV
exposure among patients, caregivers, and family
members [44]. Our experience suggests that prophy-
lactic palivizumab should be administered to high-
risk HSCT patients to contain nosocomial RSV
transmission, in conjunction with the simple and
inexpensive preventive measure of hand washing.
Active surveillance for respiratory viruses should be
implemented, as should rapid and strict adherence
to all preventive infection control measures. Further
studies are needed to assess the role of prophylactic
palivizumab in nosocomial RSV and whether this
intervention is cost effective.ACKNOWLEDGMENTS
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